Is Valeant Pharmaceuticals International, Inc. (VRX)’s Fuel For Real? The Stock Just Increased Again

March 14, 2018 - By Henry Gaston

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.09, from 1.08 in 2017Q2. It turned negative, as 43 investors sold Valeant Pharmaceuticals International, Inc. shares while 68 reduced holdings. 27 funds opened positions while 83 raised stakes. 169.87 million shares or 1.18% less from 171.89 million shares in 2017Q2 were reported.
Hightower Advsr Ltd Company stated it has 0.02% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Winslow Evans Crocker, a Massachusetts-based fund reported 4,000 shares. National Bank & Trust Of Nova Scotia reported 0.08% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Schroder Invest Management Group owns 36,500 shares for 0% of their portfolio. 11,894 were reported by Iron Fincl Ltd Limited Liability Company. Cornerstone Advisors holds 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 160 shares. Armstrong Henry H Assoc Incorporated holds 0.24% or 93,458 shares in its portfolio. Diamond Hill invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 1.58 million are held by Legal And General Gru Public Limited. 200 are owned by M&R Capital Management. First Allied Advisory Services accumulated 0.01% or 11,665 shares. Peak6 Invs Lp has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Acadian Asset Management Lc reported 239,525 shares. Commonwealth Savings Bank Of Australia reported 165,495 shares. Mackenzie Fin holds 129,398 shares.

Since March 8, 2018, it had 1 insider buy, and 0 insider sales for $153,400 activity.

The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is a huge mover today! The stock increased 5.41% or $0.87 during the last trading session, reaching $16.95. About 18.68 million shares traded or 26.98% up from the average. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has declined 48.51% since March 14, 2017 and is downtrending. It has underperformed by 65.21% the S&P500.
The move comes after 8 months positive chart setup for the $5.91 billion company. It was reported on Mar, 14 by We have $18.31 PT which if reached, will make NYSE:VRX worth $473.04 million more.

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on May, 8. They expect $0.66 EPS, down 76.43 % or $2.14 from last year’s $2.8 per share. VRX’s profit will be $230.24M for 6.42 P/E if the $0.66 EPS becomes a reality. After $0.98 actual EPS reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -32.65 % negative EPS growth.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Among 28 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 7 have Buy rating, 6 Sell and 15 Hold. Therefore 25% are positive. Valeant Pharmaceuticals Intl had 159 analyst reports since July 21, 2015 according to SRatingsIntel. TD Securities maintained the shares of VRX in report on Friday, November 3 with “Hold” rating. Mizuho downgraded the stock to “Underperform” rating in Wednesday, November 23 report. The firm has “Sector Outperform” rating given on Tuesday, October 20 by Scotia Capital. The rating was initiated by Deutsche Bank with “Hold” on Tuesday, September 20. The firm has “Overweight” rating given on Wednesday, March 16 by JP Morgan. BMO Capital Markets maintained the shares of VRX in report on Monday, October 30 with “Hold” rating. The firm has “Equal Weight” rating by Barclays Capital given on Friday, February 10. The firm earned “Equal-Weight” rating on Thursday, December 15 by Morgan Stanley. The stock has “Buy” rating by Jefferies on Friday, August 11. The rating was downgraded by JP Morgan on Thursday, December 14 to “Underweight”.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: which released: “Intangibles Hold the Key to Valeant Pharmaceuticals Intl Inc Stock” on March 01, 2018, also with their article: “How Valeant Pharmaceuticals Intl Inc Can Give You a 750% Return” published on March 14, 2018, published: “Valeant Pharmaceuticals Intl Inc Stock Tumbles on Q4 Revenue Miss” on February 28, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: and their article: “Valeant Pharmaceuticals Intl Inc. Sure Has Fight in it” published on February 26, 2018 as well as‘s news article titled: “Valeant Pharmaceuticals Intl Inc.: Get Ready for a Massive Opportunity” with publication date: February 14, 2018.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $5.91 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 2.48 P/E ratio. Diversified Products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: